Management of Atrial Fibrillation in Patients with Profound Shock on Maximal Vasopressor Support

Immediate Hemodynamic Assessment

In patients presenting with acute hemodynamic collapse (systolic blood pressure < 70 mm Hg, loss of consciousness, pulmonary edema, or ongoing myocardial ischemia), immediate electrical cardioversion is recommended rather than pharmacologic rate control. American Heart Association/American College of Cardiology (AHA/ACC) guideline. 1

Intravenous β‑blockers (e.g., esmolol, metoprolol) are contraindicated in decompensated heart failure or shock because they can further reduce cardiac output and precipitate cardiovascular collapse; they carry a Class III (Harm) recommendation. AHA/ACC guideline. 1
Intravenous calcium‑channel blockers (e.g., diltiazem, verapamil) are also contraindicated in decompensated heart failure or shock due to their negative inotropic effect; they likewise have a Class III (Harm) recommendation. AHA/ACC guideline. 1

Loading dose: 150 mg IV administered over 10 minutes. AHA/ACC guideline. 1
Maintenance infusion: 1 mg/min for the first 6 hours, then reduced to 0.5 mg/min thereafter. AHA/ACC guideline. 1
Safety profile: Hypotension occurs in approximately 16 % of patients receiving IV amiodarone; if it develops, the infusion rate should be slowed. AHA/ACC guideline. 1
Safety profile: Bradycardia and atrioventricular block occur in about 4.9 % of patients; infusion should be slowed or discontinued if severe. AHA/ACC guideline. 1

Loading regimen: 0.25 mg IV initially, followed by 0.25 mg every 2 hours up to a total of 1.5 mg. AHA/ACC guideline. 1
Maintenance regimen: 0.125–0.375 mg daily administered IV or orally. AHA/ACC guideline. 1
Onset of action: Clinical effect typically requires 60 minutes or longer, which is slower than amiodarone. AHA/ACC guideline. 1
Limitation: Digoxin should not be used as the sole agent for conversion of paroxysmal atrial fibrillation. AHA/ACC guideline. 1

In truly unstable patients, delaying electrical cardioversion while attempting pharmacologic therapy is discouraged; prompt cardioversion should be performed. European Society of Cardiology (ESC) guideline. 3

Continuous blood‑pressure monitoring is essential during IV amiodarone infusion to detect rapid hypotension. AHA/ACC guideline. 1
Resuscitation equipment (e.g., vasopressors, inotropes, volume expanders) must be immediately available because amiodarone can precipitate bradycardia or AV block. AHA/ACC guideline. 1
Electrolyte assessment (especially potassium and magnesium) should be performed before and during therapy; hypokalemia or hypomagnesemia increases the risk of torsades de pointes. ESC guideline. 3

Anticoagulation should be initiated immediately in all patients with atrial fibrillation, irrespective of whether cardioversion is planned. ESC guideline. 3
After cardioversion, anticoagulation must be continued for at least 4 weeks, and indefinitely if the patient has persistent stroke‑risk factors. ESC guideline. 3